Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

Inna M Chen, Nicholas Willumsen, Christian Dehlendorff, Astrid Z Johansen, Benny V Jensen, Carsten P Hansen, Jane P Hasselby, Stig E Bojesen, Per Pfeiffer, Svend E Nielsen, Niels H Holländer, Mette K Yilmaz, Morten Karsdal, Julia S Johansen, Inna M Chen, Nicholas Willumsen, Christian Dehlendorff, Astrid Z Johansen, Benny V Jensen, Carsten P Hansen, Jane P Hasselby, Stig E Bojesen, Per Pfeiffer, Svend E Nielsen, Niels H Holländer, Mette K Yilmaz, Morten Karsdal, Julia S Johansen

Abstract

Hyaluronan (HA) and collagen are highly expressed in pancreatic cancer (PC) stroma. HA and collagen accumulation increase tumor interstitial fluid pressure, compromising blood flow and drug penetration. The aim of this biomarker study was to determine the clinical utility of serum HA and the propeptide of type III collagen (PRO-C3) in patients with PC. A cohort from the Danish BIOPAC study (NCT03311776) including patients with histologically confirmed pancreatic ductal adenocarcinoma (n = 809), ampullary carcinoma (n = 44), distal biliary tract cancer (n = 31), chronic pancreatitis (n = 15), intraductal papillary mucinous neoplasm (n = 41), duodenal adenoma (n = 7) and no cancer (n = 25). Healthy controls were available for serum HA (n = 141) and PRO-C3 (n = 8). The main outcome was overall survival (OS) of patients with PC in relation to pretreatment serum HA and PRO-C3 levels. Patients with PC had higher baseline serum HA and PRO-C3 than healthy subjects and patients with benign conditions. Pretreatment serum baseline HA and PRO-C3 in patients with PC were associated with poorer survival and PRO-C3 remained prognostic also after adjusting for age, performance status, stage, the presence of liver and peritoneum metastasis, and CA19-9. Detection of HA and PRO-C3 may be useful in differentiating between malignant and benign pancreatic conditions. Serum HA and PRO-C3 were prognostic for OS in patients with PC.

Keywords: PRO-C3; biomarkers; collagen type III; diagnostic biomarker; hyaluronan; pancreatic cancer; prognostic biomarker.

© 2019 UICC.

References

    1. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol 2016;55:1158-60.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
    1. The Lancet O. Pancreatic cancer: cause for optimism? Lancet Oncol 2016;17:845.
    1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002;2:897-909.
    1. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-27.
    1. Stromnes IM, DelGiorno KE, Greenberg PD, et al. Stromal reengineering to treat pancreas cancer. Carcinogenesis 2014;35:1451-60.
    1. Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res 2015;21:3561-8.
    1. Babic A, Schnure N, Neupane NP, et al. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 2018;9:145.
    1. Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 2009;9:411-8.
    1. Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One 2013;8:e67059.
    1. Tjomsland V, Niklasson L, Sandstrom P, et al. The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma. Clin Dev Immunol 2011;2011:212810.
    1. Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer. Oncotarget 2018;9:29820-41.
    1. Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res 2012;18:4266-76.
    1. Torphy RJ, Wang Z, True-Yasaki A, et al. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma. JCO Precis Oncol 2018;2018:1-12.
    1. Kota J, Hancock J, Kwon J, et al. Pancreatic cancer: Stroma and its current and emerging targeted therapies. Cancer Lett 2017;391:38-49.
    1. Vennin C, Murphy KJ, Morton JP, et al. Reshaping the tumor Stroma for treatment of pancreatic cancer. Gastroenterology 2018;154:820-38.
    1. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-20.
    1. Knudson CB, Knudson W. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 1993;7:1233-41.
    1. Mahlbacher V, Sewing A, Elsasser HP, et al. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur J Cell Biol 1992;58:28-34.
    1. Spinelli FM, Vitale DL, Demarchi G, et al. The immunological effect of hyaluronan in tumor angiogenesis. Clin Transl Immunol 2015;4:e52.
    1. Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-64.
    1. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004;29:179-87.
    1. Hamada S, Masamune A. Elucidating the link between collagen and pancreatic cancer: what's next? Expert Rev Gastroenterol Hepatol 2018;12:315-7.
    1. Menke A, Philippi C, Vogelmann R, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 2001;61:3508-17.
    1. Willumsen N, Bager CL, Leeming DJ, et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 2013;13:554.
    1. Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015;527:525-30.
    1. Nissen NI, Karsdal M, Willumsen N. Collagens and cancer associated fibroblasts in the reactive stroma and its relation to cancer biology. J Exp Clin Cancer Res 2019;38:115.
    1. DuFort CC, DelGiorno KE, Hingorani SR. Mounting pressure in the microenvironment: fluids, solids, and cells in pancreatic ductal adenocarcinoma. Gastroenterology 2016;150:1545-1557.e1542.
    1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
    1. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-29.
    1. Singha NC, Nekoroski T, Zhao C, et al. Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. Mol Cancer Ther 2015;14:523-32.
    1. Cheng XB, Sato N, Kohi S, et al. Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One 2013;8:e80765.
    1. Drifka CR, Loeffler AG, Mathewson K, et al. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget 2016;7:76197-213.
    1. Gebauer F, Kemper M, Sauter G, et al. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance? PLoS One 2017;12:e0178703.
    1. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014;159:80-93.
    1. Rosengren S, Clift R, Zimmerman SJ, et al. Abstract 4886: PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer. Cancer Res 2016;76:4886.
    1. Shepard HM. Breaching the castle walls: Hyaluronan depletion as a therapeutic approach to cancer therapy. Front Oncol 2015;5:192.
    1. Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 2018;36:359-66.
    1. Wang S, Willumsen N, Bager C, et al. Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (A), and gemcitabine (G). J Clin Oncol 2018;36:12030-0.
    1. Anagnostopoulou E, Papanastasopoulou C, Papastamataki M, et al. Serum hyaluronic acid levels are altered in acute leukemia patients: potential prognostic implications. Acta Haematol 2017;138:44-51.
    1. Kehlet SN, Sanz-Pamplona R, Brix S, et al. Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients. Sci Rep 2016;6:30599.
    1. Peng C, Wallwiener M, Rudolph A, et al. Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. Int J Cancer 2016;138:2499-509.
    1. Ueda J, Yoshida H, Mamada Y, et al. Evaluation of the impact of preoperative values of hyaluronic acid and type IV collagen on the outcome of patients with hepatocellular carcinoma after hepatectomy. J Nippon Med School 2018;85:221-7.
    1. Wu RL, Huang L, Zhao HC, et al. Hyaluronic acid in digestive cancers. J Cancer Res Clin Oncol 2017;143:1-16.
    1. Xing RD, Chang SM, Li JH, et al. Serum hyaluronan levels in oral cancer patients. Chin Med J (Engl) 2008;121:327-30.
    1. Jensen C, Madsen DH, Hansen M, et al. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients. J Immunother Cancer 2018;6:152.
    1. Lipton A, Leitzel K, Ali SM, et al. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. Int J Cancer 2018;143:3027-34.
    1. Willumsen N, Bager CL, Kehlet SN, et al. Excessive matrix metalloprotease-mediated degradation of interstitial tissue (type I collagen) independently predicts short-term survival in an observational study of postmenopausal women diagnosed with cancer. Oncotarget 2017;8:52501-10.
    1. Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013;5:303-15.
    1. Sauerbrei W, Taube SE, McShane LM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst 2018;110:803-11.
    1. Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer 2019;18:14.
    1. Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus Pegylated recombinant human Hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol 2019;37:1062-9.
    1. Imamura T, Iguchi H, Manabe T, et al. Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas 1995;11:357-64.
    1. El-Mezayen HA, el Toson SA, Darwish H, et al. Development of a novel metastatic breast cancer score based on hyaluronic acid metabolism. Med Oncol 2013;30:404.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅